Analysts Offer Predictions for PCRX Q1 Earnings

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Stock analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for shares of Pacira BioSciences in a report issued on Monday, March 30th. HC Wainwright analyst D. Tsao expects that the company will earn $0.21 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $38.00 price target on the stock. The consensus estimate for Pacira BioSciences’ current full-year earnings is $2.41 per share. HC Wainwright also issued estimates for Pacira BioSciences’ Q2 2027 earnings at $0.37 EPS, Q3 2027 earnings at $0.41 EPS, Q4 2027 earnings at $0.49 EPS and FY2027 earnings at $1.49 EPS.

Other equities analysts have also issued reports about the stock. Zacks Research lowered shares of Pacira BioSciences from a “hold” rating to a “strong sell” rating in a research report on Monday, March 9th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Pacira BioSciences in a report on Monday, December 29th. Wall Street Zen cut shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Needham & Company LLC restated a “buy” rating and set a $30.00 target price on shares of Pacira BioSciences in a research report on Friday, January 9th. Finally, Barclays lowered their price target on shares of Pacira BioSciences from $27.00 to $25.00 and set an “equal weight” rating on the stock in a report on Thursday, March 26th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $30.25.

Pacira BioSciences Trading Up 0.8%

Pacira BioSciences stock opened at $22.79 on Wednesday. The stock has a 50-day moving average price of $22.07 and a 200 day moving average price of $23.29. The company has a market capitalization of $922.77 million, a price-to-earnings ratio of 151.93 and a beta of 0.21. Pacira BioSciences has a 52 week low of $18.80 and a 52 week high of $27.64. The company has a quick ratio of 3.28, a current ratio of 4.54 and a debt-to-equity ratio of 0.54.

Pacira BioSciences (NASDAQ:PCRX) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.57 EPS for the quarter, missing analysts’ consensus estimates of $0.85 by ($0.28). The firm had revenue of $196.87 million for the quarter, compared to analyst estimates of $201.93 million. Pacira BioSciences had a return on equity of 10.39% and a net margin of 0.97%.The business’s revenue was up 5.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.91 EPS.

Insider Buying and Selling at Pacira BioSciences

In other Pacira BioSciences news, SVP Lauren Riker sold 4,000 shares of Pacira BioSciences stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $20.81, for a total value of $83,240.00. Following the completion of the transaction, the senior vice president owned 52,313 shares of the company’s stock, valued at approximately $1,088,633.53. The trade was a 7.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Jonathan Slonin sold 3,261 shares of the company’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $22.82, for a total transaction of $74,416.02. Following the completion of the transaction, the insider owned 223,640 shares of the company’s stock, valued at approximately $5,103,464.80. This trade represents a 1.44% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 8,677 shares of company stock valued at $191,980. Company insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Pacira BioSciences

A number of large investors have recently bought and sold shares of PCRX. Hsbc Holdings PLC boosted its position in Pacira BioSciences by 7.7% during the fourth quarter. Hsbc Holdings PLC now owns 18,416 shares of the company’s stock worth $479,000 after purchasing an additional 1,316 shares in the last quarter. Vident Advisory LLC raised its stake in shares of Pacira BioSciences by 15.0% during the 4th quarter. Vident Advisory LLC now owns 23,571 shares of the company’s stock worth $610,000 after buying an additional 3,075 shares during the period. Empowered Funds LLC raised its stake in shares of Pacira BioSciences by 1.9% during the 4th quarter. Empowered Funds LLC now owns 227,605 shares of the company’s stock worth $5,890,000 after buying an additional 4,167 shares during the period. XTX Topco Ltd purchased a new position in shares of Pacira BioSciences during the 4th quarter valued at approximately $2,146,000. Finally, Millennium Management LLC lifted its position in shares of Pacira BioSciences by 73.3% during the 4th quarter. Millennium Management LLC now owns 122,606 shares of the company’s stock valued at $3,173,000 after buying an additional 51,848 shares in the last quarter. Institutional investors and hedge funds own 99.73% of the company’s stock.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.